Richard Mashaal’s Latest Growth Candidate in Healthcare Is Medigus Ltd. (MDGS)

Moreover, Medigus Ltd. (NASDAQ:MDGS) is aiming to get approval from the China Food and Drug Association (CFDA) for the distribution of MUSE which could prove to be a strong catalyst for the company in the future. With regards to the approval, it was recently announced that Golden Grand (Shanghai Golden Grand -Medical Instruments Ltd.) made an advance payment of $350,000 to Medigus as an initial deposit for the purchase of MUSE systems. Golden Grand is infact sub-contracted by Sinopharm (China National Pharmaceutical Group Corporation), which owns distribution rights for MUSE system in China, subject to the CFDA approval of course. Sinopharm will purchase at least $17.6 million worth of MUSE system and related equipment from Medigus during the four years following the CFDA giving the green light (if it does so).

Although down by over 21% over the last 12 months, Medigus’ stock has risen by more than 45% so far this year on the TLV. The healthcare sector has been one of the strongest performers lately, with year-to-date returns of about 15% and a rise of nearly 30% over the last year. Hedge funds with a strong focus on this sector like James E. Flynn‘s Deerfield Management and Kevin Kotler‘s Broadfin Capital are some of the firms, among those that we track, which have benefited from this hike.

Disclosure: None